New research from University College London (UCL) and Great Ormond Street Hospital (GOSH) indicates that effective respiratory syncytial virus (RSV) treatments for infants must target both the virus and the host’s immune response. Published in Nature Communications, the study utilized a novel lab-grown model of infant airways to demonstrate that the pediatric immune system triggers an overactive inflammatory response that contributes to severe lung damage, a mechanism distinct from how adults process the virus.

The Role of Infant Airway Biology in RSV Severity

RSV is the biggest cause of serious illness in babies, accounting for more than three million hospital admissions annually. While the virus causes wheezing and breathing difficulties in both age groups, the severity in babies is disproportionately high. According to the research team, led by Dr. Claire Smith of the UCL Great Ormond Street Institute of Child Health, the infant airway itself actively shapes the immune response, causing more significant damage than the virus alone.

By constructing a miniature model of baby lungs—using real infant airway cells, blood vessel cells, and neutrophils—researchers observed that infant cells attract significantly more white blood cells than adult cells. Once these neutrophils enter the lung tissue, they become hyper-activated, creating an inflammatory surge that can physically block a baby’s narrow airways. This discovery highlights that the damage is driven by the physical movement and activation of immune cells, rather than just chemical signaling.

Comparing Antiviral Efficacy: Remdesivir vs. RSV604

The study tested two specific antiviral drugs, remdesivir and RSV604, to determine their impact on both the virus and the subsequent immune reaction. While both drugs successfully halted viral replication, their effects on the infant immune system differed significantly.

The researchers found that RSV604 was able to calm the overactive immune response by reducing levels of a key inflammatory protein released by white blood cells. In contrast, remdesivir had no effect on this inflammatory process. This finding suggests that future clinical treatments for severe RSV in infants may require a dual-action approach: clearing the viral load while simultaneously modulating the immune system to prevent secondary lung damage.

Future Directions in Pediatric Respiratory Care

The ability to model both the virus and the immune response simultaneously offers a new pathway for drug development. Dr. Smith stated that this approach allows scientists to assess whether a treatment not only stops the virus but also protects the fragile infant airway from immune-driven inflammation. This is a critical shift in how researchers approach pediatric respiratory infections, emphasizing that “age matters” when designing therapies.

Funding for the research was provided by Animal Free Research UK and UK Research and Innovation (UKRI). Carla Owen, CEO of Animal Free Research UK, noted that the use of sophisticated human models provides a path to breakthroughs that avoid the use of animals while offering more relevant data for human patients.

Frequently Asked Questions

Why is RSV more dangerous for babies than for adults?

According to the UCL study, the infant airway actively triggers a more aggressive immune response. When white blood cells (neutrophils) enter the lungs, they become over-activated, leading to inflammation that can block a baby’s smaller, narrower airways.

What is the benefit of the new “baby lung” model?

The model uses real human infant cells to replicate the specific conditions of a baby’s respiratory system. This allows researchers to observe immune responses that animal models often fail to capture, leading to more accurate testing for future pediatric drugs.

Can current antiviral drugs treat the immune response in RSV?

The study found that not all antivirals function the same way. While some drugs like remdesivir stop the virus from multiplying, they may not address the inflammatory damage caused by the immune system. Drugs like RSV604 showed potential in also calming that overactive immune response.

Are you interested in the latest developments in pediatric medicine? Subscribe to our newsletter for updates on breakthroughs in respiratory health and research, or explore our archive to read more about how scientists are moving away from animal testing to improve patient outcomes.